Halper Sadeh LLC Encourages JAMF, CADE, AKRO, GES Shareholders to Contact the Firm to Discuss Their Rights - Cadence Bank ( NYSE:CADE ) , Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 - Akero Therapeutics ( NASDAQ:AKRO )
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis ( F4c ) due to MASH
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis ( F4c ) due to MASH ...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. ( Nasdaq - QRVO ) , First Foundation Inc. ( NYSE - FFWM ) , Akero Therapeutics, Inc. ( Nasdaq - AKRO ) , CoreCard Corporation ( NYSE - CCRD )
BALA CYNWYD, Pa., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.
Is the fourth time the charm for this Danish pharmaceutical giant?
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025. R&D pipeline progress continues ...
Halper Sadeh LLC Encourages AL, FFWM, AKRO, HNI Shareholders to Contact the Firm to Discuss Their Rights - Akero Therapeutics ( NASDAQ:AKRO ) , Air Lease ( NYSE:AL )
NEW YORK, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qorvo, Inc. ( Nasdaq - QRVO ) , First Foundation Inc. ( NYSE - FFWM ) , Akero Therapeutics, Inc. ( Nasdaq - AKRO ) , CoreCard Corporation ( NYSE - CCRD )
BALA CYNWYD, Pa., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders - Astria Therapeutics ( NASDAQ:ATXS ) , Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. ( Nasdaq - AKRO ) , CoreCard Corporation ( NYSE - CCRD ) , PB Bankshares, Inc. ( Nasdaq - PBBK ) , Air Lease Corporation ( NYSE - AL )
BALA CYNWYD, Pa., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Allogene Therapeutics ( NASDAQ:ALLO ) , Akero Therapeutics ( NASDAQ:AKRO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Andrew S.
Why Akero Therapeutics Stock Trounced the Market on Thursday
The biotech will soon have a new owner.
Why Shares in Viking Therapeutics Surged This Week
The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates AKRO, CCRD, AL, PBBK on Behalf of Shareholders - Akero Therapeutics ( NASDAQ:AKRO ) , Air Lease ( NYSE:AL )
NEW YORK, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday - Akero Therapeutics ( NASDAQ:AKRO ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Thursday. Shares of Tilray Brands, Inc. ( NASDAQ:TLRY ) rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results.
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Novo Nordisk ( NYSE:NVO ) , Akero Therapeutics ( NASDAQ:AKRO )
Novo Nordisk A/S ( NYSE:NVO ) agreed on Thursday to acquire Akero Therapeutics, Inc. ( NASDAQ:AKRO ) focused on metabolic diseases. Novo Nordisk will pay $54 per share in cash ( or an aggregated value of $4.7 billion ) at closing.
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion - Akero Therapeutics ( NASDAQ:AKRO )
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share ...
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Bagsværd, Denmark, 9 October, 2025 - Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. ( Akero ) , a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high ...
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral ...
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 - Akero Therapeutics ( NASDAQ:AKRO )
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( NASDAQ:AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral ...
Is Akero Therapeutics ( AKRO ) Stock Outpacing Its Medical Peers This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Humana (HUM) have performed compared to their sector so far this year.
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO - Akero Therapeutics ( NASDAQ:AKRO )
NEW ORLEANS, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ( "KSF" ) , announces that KSF has commenced an investigation into Akero Therapeutics, Inc. AKRO.
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Is Boston Scientific ( BSX ) Outperforming Other Medical Stocks This Year?
Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
Has Akero Therapeutics ( AKRO ) Outpaced Other Medical Stocks This Year?
Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Akero Therapeutics, Inc. ( Nasdaq: AKRO ) , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will ...
Does Akero Therapeutics ( AKRO ) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.1% in Akero Therapeutics (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
Results support potential of efruxifermin ( EFX ) to reduce risk of fibrosis progression in patients with pre-cirrhotic ( F2-F3 ) MASH Results support potential of efruxifermin ( EFX ) to reduce risk of fibrosis progression in patients with pre-cirrhotic ( F2-F3 ) MASH ...
